Compare Amgen, Inc. (AMGN) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Crispr Therapeutics AG — how do they compare? Amgen, Inc. trades at $385.6 (market cap $205.32B), while Crispr Therapeutics AG trades at $56.71 (market cap $5.54B). The key difference: Amgen, Inc. is far larger — about 37.1× Crispr Therapeutics AG's market cap, and Amgen, Inc. pays a 2.65% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amgen, Inc. for 72 Days and Crispr Therapeutics AG for 76 Days on average.
| AMGN | CRSP | |
|---|---|---|
Market Cap | $205.32B | $5.54B |
Volume | 3,201,007 | 2,995,890 |
Sector | Health | Health |
52-Week High | $444.12 | $76.78 |
52-Week Low | $271.18 | $44.34 |
Typical Hold Time | 72 Days | 76 Days |
Enterprise Value | $248.64B | $3.96B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $383.13, up 1.8% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a 22.95% net income margin and 91.47% ROE, supported by positive pipeline updates like IMDELLTRA's FDA approval. Analysts maintain a buy consensus with a $393.72 target, highlighting defensive appeal amid market volatility.
Outlook is positive due to earnings momentum and dividend stability, but risks include high debt levels and competitive pressures. The stock offers growth potential from pipeline advancements, yet investors should monitor debt management and regulatory developments for sustained performance.
CRSP is trading at $56.33, up 7.89% over 24 hours, with a bullish technical outlook supported by moving averages and ADX signals. The stock shows strong analyst sentiment with 57.9% buy ratings and a consensus price target of $67.83. Recent news highlights pipeline catalysts, including CASGEVY growth and upcoming clinical data, though financials reveal significant losses and negative margins.
Outlook hinges on pipeline execution and commercialization success, offering high growth potential in gene editing. Key risks include cash burn, clinical setbacks, and competitive pressures. Investors should weigh the speculative nature against long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
